Combination of Ranibizumab, Dexamethasone Superior to Ranibizumab Alone for Macular Edema

Why It Matters

The regimen offers ophthalmologists a more effective, lower‑burden option for RVO‑ME, potentially reshaping treatment standards and improving patient quality of life.

Key Takeaways

• Combination therapy improves BCVA more than monotherapy.
• 81% achieve ≥0.3 logMAR gain vs 51%.
• Fewer injections needed, lowering treatment burden.
• Intraocular pressure rises in 27% but resolve.
• Retrospective, 9‑month data limit long‑term conclusions.

Pulse Analysis

Retinal vein occlusion remains a leading cause of vision loss, with macular edema driving most of the functional impairment. Anti‑VEGF agents such as ranibizumab have become first‑line due to their ability to reduce fluid and improve acuity, yet the need for frequent injections creates logistical and financial strain for patients and providers. Dexamethasone implants, approved for inflammatory ocular conditions, offer a sustained release mechanism that can address the inflammatory component of edema, prompting interest in combined protocols that leverage both anti‑angiogenic and anti‑inflammatory pathways.

The recent real‑world analysis from Sanmenxia Eye Hospital demonstrates that a single ranibizumab dose followed by a dexamethasone implant within weeks can accelerate visual recovery and sustain lower central macular thickness compared with three consecutive ranibizumab shots. The combination achieved a mean BCVA improvement of –0.44 logMAR at three months and maintained a higher proportion of patients with clinically meaningful gains through nine months, while also reducing the total number of injections required. Safety signals were modest; intra‑ocular pressure elevations occurred in roughly a quarter of eyes but were medically managed and reversed, underscoring the importance of monitoring but not deterring use.

For the ophthalmic pharmaceutical market, these findings suggest a viable pathway to differentiate product portfolios and extend market share beyond monotherapy. Payers may favor regimens that lower injection frequency, potentially translating into cost savings despite the higher upfront price of the steroid implant. However, the study’s retrospective design and limited follow‑up horizon call for prospective, longer‑term trials to confirm durability and safety. If validated, sequential ranibizumab‑dexamethasone therapy could become a new standard for non‑ischemic RVO‑ME, influencing clinical guidelines and shaping future drug development strategies.